DE69940307D1 - Rekombinante anti-tumor rnase - Google Patents

Rekombinante anti-tumor rnase

Info

Publication number
DE69940307D1
DE69940307D1 DE69940307T DE69940307T DE69940307D1 DE 69940307 D1 DE69940307 D1 DE 69940307D1 DE 69940307 T DE69940307 T DE 69940307T DE 69940307 T DE69940307 T DE 69940307T DE 69940307 D1 DE69940307 D1 DE 69940307D1
Authority
DE
Germany
Prior art keywords
proteins
recombinant
ribonucleases
active
rnase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69940307T
Other languages
English (en)
Inventor
Susanna M Rybak
Dianne L Newton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69940307D1 publication Critical patent/DE69940307D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69940307T 1998-03-27 1999-03-26 Rekombinante anti-tumor rnase Expired - Fee Related DE69940307D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7975198P 1998-03-27 1998-03-27
PCT/US1999/006641 WO1999050398A2 (en) 1998-03-27 1999-03-26 Recombinant anti-tumor rnase

Publications (1)

Publication Number Publication Date
DE69940307D1 true DE69940307D1 (de) 2009-03-05

Family

ID=22152577

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69940307T Expired - Fee Related DE69940307D1 (de) 1998-03-27 1999-03-26 Rekombinante anti-tumor rnase

Country Status (6)

Country Link
EP (1) EP1068332B1 (de)
AT (1) ATE420961T1 (de)
AU (1) AU755147B2 (de)
CA (1) CA2324646A1 (de)
DE (1) DE69940307D1 (de)
WO (1) WO1999050398A2 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869604B1 (en) 1998-03-27 2005-03-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant anti-tumor RNAse

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2232860T3 (es) * 1996-02-21 2005-06-01 Us Gov Health & Human Serv Proteinas recombinantes de ribonucleasa.
US6649392B1 (en) * 1996-04-04 2003-11-18 The United States Of America As Represented By The Department Of Health And Human Services Mutant form of a cytotoxic ribonucleolytic protein which allows production by recombinant methods
US6395276B1 (en) * 1997-05-02 2002-05-28 Immunomedics, Inc. Immunotoxins directed against malignant cells

Also Published As

Publication number Publication date
CA2324646A1 (en) 1999-10-07
ATE420961T1 (de) 2009-01-15
WO1999050398A2 (en) 1999-10-07
EP1068332B1 (de) 2009-01-14
AU755147B2 (en) 2002-12-05
WO1999050398A3 (en) 1999-12-23
EP1068332A2 (de) 2001-01-17
AU3207499A (en) 1999-10-18

Similar Documents

Publication Publication Date Title
ZA200200789B (en) Multiple cytokine-antibody complexes.
ATE407697T1 (de) Erythropoietin immunglobulin fusionsproteine
WO1999002552A3 (en) Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof
EP1553975B8 (de) Optimierte fc-varianten und herstellungsverfahren dafür
AU2433901A (en) Chimeric natriuretic peptides
NZ502392A (en) Interleukin-18 binding proteins (IL-18BP) their preparation and use in pharmaceuticals
WO2001016114A3 (en) Heterocyclic compounds and methods for modulating cxcr3 function
DE69435049D1 (de) Chimäre proteine zur vermeidung der komplementaktivierung
DE59708952D1 (de) Fusionspolypeptid zur beeinflussung von wechselwirkungen zwischen proteinen
IN2004CH02621A (en) Low-cost production of peptides
NO20033673L (no) Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur
PL331240A1 (en) Cut off soluble tumour necrosis factor receptors of i and ii type
DK1214344T3 (da) Dipeptidylpeptidaser
WO2020247388A8 (en) Il-2alpha receptor subunit binding compounds
MXPA05003887A (es) Antagonistas il - 15.
CR20230178A (es) Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
DE69940307D1 (de) Rekombinante anti-tumor rnase
AU7525398A (en) Inhibitors for urokinase receptor
CA2151381A1 (fr) Lipase gastrique du chien recombinante et compositions pharmaceutiques
MXPA04002103A (es) Una proteina de union a caspasa-8, su preparacion y uso.
WO2000068416A3 (de) Methoden zur auffindung von proteasen, die spezifisch membrangebundene substrate spalten
GB2360772B (en) Compounds for targeting
WO2002052022A3 (en) Selective cytotoxic fusion proteins
WO2000042063A3 (de) Peptide zur inhibierung von hbv-core-proteinen
DE60040668D1 (de) Antibakterielles protein chlamysin-b, dafür kodierendes gen und ein expresionssystem dafür

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee